Big Pharma Gave Up on Mental Health… But Now an Innovative Biotech Has Stepped up with a Breakthrough That Could Change Everything

It’s the most surprising pharmaceutical about-face in history.

Despite raking in billions of dollars in profits from their antidepressant and anti-anxiety drugs, Big Pharma has pretty much abandoned the search for new mental‑health treatments.^[1]

Perhaps that’s because its drugs have failed miserably… come with a pile of nasty side-effects that are often worse than the disease itself… and have barely made a dent in the mental health crisis enveloping the world.

In fact, even now, more than 30 years after the introduction of Prozac, 400 million people worldwide suffer from debilitating depression and anxiety.^[2]

Worse yet, Big Pharma is out of answers, and has moved on from mental health, redirecting their resources toward headline-grabbing health issues such as cancer and autoimmune diseases — illnesses with clear biological targets for measuring improvement.

The company we’re talking about is a NASDAQ biotech called Helus Pharma (NASDAQ: HELP), and it’s developing powerful new pharmaceutical drugs that clinical trials show may provide a safe and powerful way to effectively treat depression and anxiety.

That’s because its drugs are designed to “rewire” the brain (in a good way) and get adults with from depression and anxiety back to their real selves in no time.

They do this by disrupting the brain’s rigid activity patterns, promoting new connections and enhancing its ability to adapt and reorganize those connections.

We realize that might sound like scientific gobbledygook, but what really matters is that, as you’ll see, clinical trials already appear to show that the drugs work wonders and their effectiveness is long-lasting. Better yet, initial clinical trials show no adverse side effects.

The breakthrough new drugs Helus Pharma is developing have their origin in a medical revolution you may have never heard about.

Research from Some of the Most Prestigious Institutions in the World

Naturally derived compounds — many sourced from plants, fungi or other organic materials — have a long historyof shaping modern medicine.

Aspirin, originally developed from willow bark, is a classic example of how nature-based compounds can deliver powerful, clinically proven benefits.

Today, researchers at leading medical and academic institutions are continuing this work, studying a range of naturally occurring substances for their potential to support mental health.

Repeated findings show that, when carefully developed and administered in controlled medical settings, naturally occurring compounds like psilocybin can play a meaningful role in improving outcomes for patients struggling with serious mental disorders.

Some institutions studying these compounds include…

• Johns Hopkins Medicine^[1]
• Yale School of Medicine^[2]
• University of California San Francisco^[3]
• NYU Langone Health Center^[4]
• Imperial College London^[5]
• Stanford University^[6]
• University of California, Los Angeles (UCLA)^[7]
• University of California, San Diego (UCSD)^[8]

But academic validation is only the first step.

Turning promising natural compounds into reliable, scalable medical treatments requires far more than discovery. It demands precision, consistency, and regulatory-grade manufacturing.

That’s where pharmaceutical engineering enters the picture.

And now Helus Pharma (NASDAQ: HELP) is building on all that research to engineer novel compounds that show remarkable promise in treating mental health disorders.

This means the company’s scientists are creating synthetic molecules specially engineered to be faster and more effective, and to have a more predictable and durable therapeutic impact than patients will get from just consuming the natural compound itself.

For you as an investor, this also makes Helus Pharma a more attractive investment because unlike the natural compounds themselves, these novel compounds can be patented.

And that gives Helus Pharma exclusive rights until at least 2041.

The company has already filed more than 350 patents on its compounds, and more than 100 of them have been granted.

That’s more than any other company researching the same class of molecules.^[1]

More importantly, however, is the success Helus Pharma (NASDAQ: HELP) is already having with clinical studies on the initial drugs in its pharmaceutical pipeline.

That success is the first of my…

Seven Surprising Reasons Why Helus Pharma Could Be a Profitable Investment Opportunity for You

My research into Helus Pharma (NASDAQ:HELP) reveals a cutting-edge company with the scientific breakthroughs, clinical proof, money, and vision to bring life-changing results to millions of people all over the world.

All while potentially handing windfall profits to savvy investors who jump into its stock now.

Let’s take a closer look…

Reason #1: Clinical Studies are Already Bringing Astonishingly Positive Results for Helus’s Flagship Drugs

Helus Pharma’s (NASDAQ: HELP) initial focus is on the treatment of two of the world’s most common mental health problems:

1) Major Depressive Disorder (MDD); and…
2) Generalized Anxiety Disorder (GAD)…

…disorders that impact more than 300 million people worldwide.

With that in mind, it has taken two of its patented novel compounds and is in the process of turning them into pharmaceutical drugs designed to effectively treat these problems.

The first is called HLP003, and it’s a proprietary deuterated novel serotonergic agonist (“NSA”) used as an adjunctive treatment for Major Depressive Disorder.

Wr realize that’s an exhausting mouthful, so let me quickly break it down.

• Novel serotonergic agonists or NSAs are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.
• “Deuterated” means the drug has been engineered at the molecular level to slow down how quickly the body breaks it down. This makes the NSA last longer in the body and work more predictably.

This could also translate to more predictable dosing and a shorter clinic time per session, making treatments more scalable.

That statistic is worth repeating — every single person participating in the Phase 2 Clinical Trial referenced above showed improvement in addressing depression.

And an astounding 71% reported complete remission of their depressive symptoms 12 months after treatment — something that’s almost unheard-of with antidepressants, especially in only two doses.

All without any significant side-effects reported.

Better yet, the results were good enough to quickly move HLP003 to Phase 3 trials.

Phase 3 is designed to test how HLP003 performs compared to existing treatments or placebos. They typically involve hundreds to thousands of patients and are the final major step before Helus Pharma (NASDAQ: HELP) can apply for FDA approval.

The company’s Phase 3 “Paradigm” program got underway in mid-2025 with the first of two important studies.

The first — the “APPROACH” study — has enrolled 220 participants across 45 clinical sites in the U.S., with topline data expected in the fourth quarter of 2026.

The company is also gearing up for a second Phase 3 “EMBRACE” study that targets 330 international participants with moderate to severe major depressive disorder. The company has been granted approval to launch the study in Australia, Ireland, Poland, Greece, and the United Kingdom.

Patients who complete either of those two studies can roll over into “EXTEND,” an open-label extension designed to gather long-term durability data, which will measure how long the treatment’s benefits last after dosing.

Better yet, because of the clinical success Helus Pharma has had with HLP003, it has been granted a coveted “Breakthrough Therapy Designation” from the FDA, which acknowledges that the drug has the potential to meet a significant unmet medical need.

It’s important because it can help speed the drug on its way through the regulatory maze. More on that in a moment.

Helus’s Anxiety Drug Has Entered Phase 2 Trials

Helus Pharma’s (NASDAQ: HELP) second new drug in development is called HLP004. It’s a proprietary NSA for the treatment of Generalized Anxiety Disorder.

After the successful completion of its Phase 1 studies, the company enrolled 36 people in a Phase 2 trial designed to evaluate the safety and efficacy of HLP004 at 12 weeks after first dose.

The study’s effectiveness will be evaluated using the Hamilton Anxiety Rating Scale, with the first results expected in Q1 2026.

This is big news for investors considering that when Gilgamesh Pharmaceuticals — which is developing a similar drug — reached this point recently, the drug was almost immediately acquired by pharma giant AbbVie (NYSE: ABBV) for up to $1.2 billion.

In any case, Helus Pharma’s light speed clinical progress — boosted by the FDA’s Breakthrough Therapy Designation for HLP003 — means that it’s that much closer to potential approval, sales and profits…

…and its stock value could soar as word gets about the company’s success.

Let me give you a quick example:

You’ve no doubt heard of the drug Ozempic. Originally prescribed as a treatment for Type 2 diabetes, it was soon recognized for its ability to help patients lose weight.

And doctors began prescribing it “off-label” to their overweight patients — “off-label” meaning for a use other than what the FDA approved it for.

The drug’s surprising success soon sent sales soaring — largely because the number of obese people in the U.S. is nearly triple that of those suffering from Type II diabetes.

The result: Novo Nordisk — the company behind Ozempic — saw its market cap explode from $130 billion when the drug was launched to $232 billion today.

Ozempic accounted for nearly $5 billion of Novo Nordisk’s revenue in Q1 2025 alone!

The company was swimming in Ozempic cash. Some investors nearly doubled their money. And that’s on a hundred-billion-dollar large cap stock. Just imagine the return if Novo Nordisk had been a small cap biotech like Helus Pharma (NASDAQ: HELP).

Better yet, though HLP003 is designed to treat Major Depressive Disorder, its amazing impact on the brain means that it could potentially be prescribed for multiple off-label uses.

These could include issues often associated with depression — substance abuse disorders, smoking cessation, and even PTSD — making the potential for these new drugs even bigger… and the returns to investors potentially even more lucrative.

Reason #2: Millions of people around the world are desperate for the relief Helus Pharma’s new drugs in development could offer … and that could, once approved, send sales and profits flying

As you’ve seen, the numbers related to the global mental health crisis are absolutely terrifying:

Believe it or not, more than 332 million people worldwide suffer from Major Depressive Disorder (MDD ), while 359 million suffer from anxiety disorders.

Most everyone has a friend or family member that has struggled with mental health issues.

No wonder the research firm Global Market Insights reports that antidepressant sales hit $18.7 billion worldwide in 2024. And sales are expected to better than double by 2034 to $37.9 billion.

And that’s for drugs that don’t even work all that well. In fact, as many as 30-50% of patients don’t respond effectively to current drugs at all.

And let’s not forget the brutal side effects those drugs often bring, including sexual dysfunction, weight gain, nausea, insomnia, fatigue, and even anxiety, among others.

By contrast, Helus Pharma’s (NASDAQ: HELP) breakthrough drugs have shown limited side effects in clinical trials.

Considering the success the company has had with its drug development thus far, we expect to see Helus Pharma (NASDAQ: HELP) snag a significant share – once clinical trials and FDA approval are completed.

No wonder a number of Wall Street analysts now rate Helus Pharma as a “Strong Buy,” with profit expectations ranging from 328% to 757%.

Reason #3: RFK Jr. is leading the charge to open up the world to new therapies

It has been more than 50 years since the U.S. government outlawed natural compounds like psilocybin and DMT and banned medical research into their efficacy as pharmaceuticals.

But times have changed and attitudes have softened. And that has given treatments derived from these compounds a second chance to shine as they enjoy a medical renaissance of their own.

As you’ve seen, the U.S. and the U.K. are already allowing research at a number of respected universities and research institutions.

And the astonishingly positive results this research is getting is creating new opportunities for further research.

Better yet, President Trump’s Secretary of Health and Human Services, RFK Jr., is running the show now and he has shown a remarkable openness to innovative new therapies like those being developed by Helus Pharma (NASDAQ: HELP)

On top of that, healthcare providers are on board, as well..

A February 2025 Helus Pharma survey of more than 430 mental healthcare providers worldwide found:

• 79% noted rising patient interest in pharmaceutical drugs derived from natural compounds like psilocybin
  
• 89% recognize their therapeutic potential
  
• 94% are willing to integrate them into their treatment plans once they’re approved
  

Bottom line: It seems fairly certain that if and when they’re approved Helus Pharma’s (NASDAQ: HELP) proprietary, life-changing new treatments could take the world by storm and bring a surge of revenue and profits to the company as its breakthrough therapies meet crushing demand.

Reason #4: The FDA’s “Golden Ticket” Is Clearing the Way for Breakthrough New Therapies

As you know, the FDA holds immense power over pharmaceutical companies.

It serves as the gatekeeper for drug approval, marketing, and ongoing regulation in the United States — the world’s largest pharmaceutical market.

And even with Trump’s efforts at deregulation and Kennedy’s “Make America Healthy Again” push to speed up treatments that are shown to be safe, bringing a new drug to market is generally time-consuming, laborious and expensive …

… and so any drug that has the opportunity to “fast track” the approval process has a significant leg up on its competitors.

Enter the Breakthrough Therapy Designation, or BTD — designation recently awarded to Helus Pharma’s HLP003.

Companies applying for a BTD have to meet some very specific criteria.

The drug must target a serious or life-threatening disease or condition where there’s a clear unmet medical need — either no treatments exist, or current options are inadequate.

HLP003 clearly fits the bill.

Plus, the drug’s early-stage clinical data must show that it offers substantial improvement over existing therapies. This could mean better efficacy, fewer side effects, or a novel mechanism of action.

Again, HLP003 fits the bill.

For Helus Pharma (NASDAQ: HELP), HLP003’s BTD is a “golden ticket” that expedites the development pathway for HLP003. Among other things, Helus benefits from…

•  Fast-Tracked Development: The FDA offers intensive guidance, often involving senior officials, to streamline clinical trials and reduce development timelines — potentially cutting years off the path to market.
  
•  Priority Review: BTD drugs get a faster review process (typically 6 months instead of 10) once a New Drug Application (NDA) or Biologics License Application (BLA) is submitted.
  
•  Rolling Review: Companies can submit completed sections of their application as they go, rather than waiting to compile everything, speeding up the overall approval process.
  
•  Enhanced Collaboration: The FDA commits to working closely with the company, providing advice on trial design, endpoints, and data requirements to ensure efficiency and success.
  

BTD signals investors, researchers, and the medical community that HLP003 could be a game-changer with blockbuster potential. It doesn’t guarantee approval, but it significantly boosts the odds.

Think of it this way, a BTD is kind of like a Fast Pass at Disney World — it’s a limited access, exclusive designation that allows the holder to “skip to the head of the line” … and when time is money, this “fast pass” could be almost literally priceless.

Of course, Helus Pharma still has to ride the approvals roller coaster … but with direct access to top FDA officials and an expedited review process, the ride is potentially much smoother.

Most importantly for investors, a BTD has the potential to allow Helus Pharma (NASDAQ: HELP) to bring HLP003 to market sooner, maximizing profits before patents expire or competitors catch up.

A Breakthrough Therapy Designation is massive for a Big Pharma company, but for a small-cap stock, it is absolutely a game-changer.

Clinical Trials to Billion-Dollar Paydays

This “golden ticket” has a history of transforming small cap companies and, often, a savvy investor’s portfolio.

For a small-cap, this designation can take them from under-the-radar to blockbuster status virtually overnight.

For example…

Breakthrough #1
Luxturna by Spark Therapeutics

Spark Therapeutics, a small-cap biotech, saw its profile skyrocket after its drug Luxturna received Breakthrough Therapy Designation. The product went on to became the first FDA-approved gene therapy for a genetic disease in December 2017.

What happened to Spark Therapeutics?

The company’s valuation surged, and in 2019, Roche acquired Spark for an astonishing $4.3 billion — a massive leap from its earlier small-cap status.

Breakthrough #2:
Kanuma by Synageva BioPharma

In 2013, Synageva received BTD for sebelipase alfa (brand name Kanuma), a treatment for a rare condition called lysosomal acid lipase deficiency.

At the time, Synageva’s market cap was below $2 billion. The stock surged over 50% in the days following the announcement, and the company was later acquired by Alexion Pharmaceuticals for a massive $8.4 billion

Breakthrough #3:
Amtagvi by Iovance Biotherapeutics

In 2018, Iovance secured a BTD for the attractively named LN-144 (later rebranded as Amtagvi), a Tumor-Infiltrating Lymphocyte (TIL) therapy for advanced cervical cancer.

At the time the BTD was announced, the company’s market cap hovered around $1 billion. In the immediate aftermath of the announcement, the stock rose roughly 40%.

While the company has seen some volatility through the years, the BTD marked a turning point that fueled a multi-year upward trend, with its market cap eventually exceeding $3 billion.

My analysis shows that HLP003’s Breakthrough Therapy Designation could have a similar impact on Helus Pharma (NASDAQ: HELP)… and it’s just one more reason why I’m recommending that my subscribers begin their due diligence on this astounding company immediately.

Reason #5: Helus Pharma is Building a Robust New Drug Pipeline

Despite all the progress we’ve already described Helus Pharma (NASDAQ: HELP), isn’t resting on its laurels. It’s working day and night to isolate additional molecules for the creation of new drugs to treat a variety of mental health conditions.

As I mentioned, it has already filed 350 patent applications on the proprietary molecules it has developed. And more than 100 of those patents have been granted.

The company is pursuing research on a number of fronts with the expectation that its drugs will have an impact on a number of other conditions related to mental health.

These potentially include PTSD, bipolar disorder, substance use/addiction disorders, eating disorders, cluster headaches/migraine, and chronic pain management.

Many hundreds of millions of people suffer from these disorders and there is already strong evidence that pharmaceuticals derived from natural compounds can help them thanks to their ability to “rewire” the brain.

While Helus Pharma (NASDAQ: HELP) is primarily focused on HLP003 and HLP004, it’s also devoting considerable resources to developing a pipeline of drugs that could keep the company growing for years to come.

Reason #6: Helus Pharma Boasts World Class Leadership and Has Plenty Of Cash

Over the years, I’ve seen plenty of companies with great ideas and all the advantages in the world fall into mediocrity because they didn’t have a strong leadership team with the experience and talent to take it the distance.

With that in mind, I always do a deep dive into a company’s leadership team before I recommend looking at its stock.

When it comes to Helus Pharma (NASDAQ: HELP), it boasts a strong executive line-up — a line up with the experience and talent I’m looking for. It’s just one more reason I’m so excited about this company.

One of the most impressive things about the team is the cash position they’ve put the company in. Unlike many early-stage players we’ve seen scraping by and burning through funds, Helus Pharma stands out as a powerhouse with staying power.

In fact, in a recent offering, the company added $175 million in new investments from a stellar line up of investment firms and hedge funds.

The increased the company’s cash position to a healthy $248 million — $22.8 million of which they used to pay off outstanding convertible debenture bonds, retiring the debt in full.^[1]

This is a substantial war chest for a company of Helus Pharma’s size, and it means the company has the fuel to keep its operations humming, push its clinical trials forward, research additional potential therapies, and even potentially snap up strategic acquisitions.

Reason #7: Big Pharma could go on a small-cap buying binge

Despite the initial turbulence around RFK Jr’s nomination, many Big Pharma stocks have recovered … and you can bet that dozens of big pharmaceutical companies are looking to insulate their stocks against future shocks by watching the sector carefully, looking to get their hands on a successful breakthrough via acquisition.

And when they go on the hunt, it will be good for just about every biotech stock, driving investor interest and sending prices upwards.

We don’t know whether or not a big pharmaceutical will make a play for Helus Pharma (NASDAQ: HELP), but with all it’s got going for it, it wouldn’t surprise us a bit.

And, if past experience is any indication of what we could expect, a potential acquisition could send the stock price skyrocketing.

When Big Pharma Acquires a Small Company, Early Investors Can Enjoy BIG Profits

For example…

• In 2021, Jazz Pharmaceuticals paid $220 per share to acquire GW Pharmaceuticals, handing shareholders a 50% profit over the previous day’s closing price.^[1]
• In 2019, Bristol-Myers Squibb acquired Celgene for $74 billion in a cash-and-stock acquisition, which handed shareholders a 54% premium over the company’s prior close.^[2]
• In 2023, Pfizer bought cancer-drug maker Seagen for about $43 billion. Shareholders walked away with $229 a share — a roughly a 30–40% premium over its recent trading price.^[3]
• In 2018, Japan’s Takeda agreed to buy Shire for roughly $62 billion, in stock and cash for a roughly 60–69% premium to where Shire traded before Takeda’s interest became public.^[4]
• In 2019, AbbVie moved to acquire Allergan for about $63 billion in cash and stock. Allergan shareholders received about a 45% premium to the company’s prior closing price.^[5]
• In 2020, Bristol-Myers Squibb acquired MyoKardia for $13.1 billion, handing Myocardia shareholders a 60% premium over the company’s prior closing price.^[6]

Now, don’t get us wrong. We never recommend investing in a company based solely on its acquisition potential.

It’s always a possibility, but never something to count on. Look at it instead as potential icing on the cake.

Bottom line: With Helus Pharma (NASDAQ: HELP), we see all the makings of a company that could be going places and potentially handing early investors nice returns. And getting in now, while the company is still in its early stages could bring you some rich rewards — whether the company is acquired or not.

Start Your Due Diligence Today

There’s more to the Helus Pharma (NASDAQ: HELP) story than we have the room to discuss here.

I urge you to start your due diligence on this company today, while the company is still under the radar of Wall Street and most investors.

It could turn out to be a terrific profit opportunity for you with a company that is poised to potentially change the lives of millions of people all over the world.

Click Here to Start Your Due Diligence

Best regards,

IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of Helus Pharma (NASDAQ: HELP). Rebel Investors Club is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, Helus Pharma (NASDAQ: HELP) provided advertising agencies with a total budget of approximately $2,914,712 and is the sole source of funds to cover the costs associated with creating, printing and distribution of this advertisement. From that total budget, Rebel Investors Club was paid $500,000 as a research fee and for the production and placement of additional advertising media for this campaign. The advertising agencies will retain any excess sums after all expenses are paid. Rebel Investors Club may receive subscription revenue in the future from new subscribers as a result of this advertisement for its newsletter.
While this advertisement is being disseminated and for a period of not less than 90 days thereafter, Rebel Investors Club , the advertising agencies, and their respective officers, principals, or affiliates will not sell securities of Helus Pharma (NASDAQ: HELP). If successful, this advertisement will increase investor and market awareness of Helus Pharma (NASDAQ: HELP) and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement, the advertising agencies and Rebel Investors Club do not purport to provide a complete analysis of Helus Pharma (NASDAQ: HELP) or its financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors.
This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about Helus Pharma (NASDAQ: HELP). Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in Helus Pharma (NASDAQ: HELP) SEC filings. Investing in microcap securities such as Helus Pharma (NASDAQ: HELP) is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Rebel Investors Club cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions.
This advertisement contains forward-looking statements, including statements regarding expected continual growth of Helus Pharma (NASDAQ: HELP) and/or its industry. The advertising agencies and Rebel Investors Club note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect Helus Pharma (NASDAQ: HELP) actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for Helus Pharma (NASDAQ: HELP) products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc.
Rebel Investors Club is the publisher’s trademark. All trademarks used in this advertisement other than Rebel Investors Club are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies and Rebel Investors Club are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.